Edgewise Therapeutics doses first patient in Phase 2 EQUINOX-HFpEF trial
Edgewise Therapeutics (EWTX) dosed the first patient in its Phase 2 EQUINOX-HFpEF trial of EDG-15400.
Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
1 result loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Edgewise Therapeutics (EWTX) dosed the first patient in its Phase 2 EQUINOX-HFpEF trial of EDG-15400.